Cambridge Nutritional Science (CNSL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 3.95p
   
  • Change Today:
      0.000p
  • 52 Week High: 4.03
  • 52 Week Low: 1.73
  • Currency: UK Pounds
  • Shares Issued: 237.95m
  • Volume: 127,670
  • Market Cap: £9.40m

Omega challenges government on repayment after Covid test contract failure

By Josh White

Date: Friday 10 Dec 2021

LONDON (ShareCast) - (Sharecast News) - Omega Diagnostics updated the market on its contract with the UK Department of Health and Social Care (DHSC) to provide manufacturing capacity for Covid-19 lateral flow antigen tests on Friday, indicating it was in disagreement with the government on an alleged repayment requirement.
The AIM-traded firm had previously said it was unable to move into the second phase of the contract, which would have seen Omega progress to manufacturing tests using government-furnished equipment.

It said on Friday that it had received confirmation from the DHSC, acknowledging that the contract expired on 1 October, with a request that Omega submit a proposal for repaying the pre-production payment of £2.5m, net of VAT.

The company's board, having taken initial legal advice, said it did not believe that Omega was required to repay the pre-production payment, adding that it would respond in writing as requested.

It said it would continue to take further legal advice on the matter, hoping to reach a resolution swiftly.

"It is clearly disappointing to receive this request for repayment given the efforts we have gone to ensure manufacturing capacity for Covid-19 lateral flow test was available for the DHSC and that we did not progress to the second phase of the contract due to the lack of confirmation from the DHSC regarding which test they require us to manufacture," said chief executive officer Colin King.

"Acting in good faith we used these pre-production payments, along with our own funds, to upgrade our manufacturing facilities to be able to integrate the government-furnished equipment and bring on the additional staff required to be able to supply the DHSC using our UK-based volume manufacturing services.

"We therefore are confident that, having sought legal advice, we will not be required to make this repayment."

At 1456 GMT, shares in Omega Diagnostics were down 26.15% at 24p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CNSL Market Data

Currency UK Pounds
Share Price 3.95p
Change Today 0.000p
% Change 0.00 %
52 Week High 4.03
52 Week Low 1.73
Volume 127,670
Shares Issued 237.95m
Market Cap £9.40m

CNSL Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
78.00% above the market average78.00% above the market average78.00% above the market average78.00% above the market average78.00% above the market average
89.19% above the sector average89.19% above the sector average89.19% above the sector average89.19% above the sector average89.19% above the sector average
Income Not Available
Growth
46.27% below the market average46.27% below the market average46.27% below the market average46.27% below the market average46.27% below the market average
61.11% below the sector average61.11% below the sector average61.11% below the sector average61.11% below the sector average61.11% below the sector average

CNSL Dividends

No dividends found

Trades for 03-May-2024

Time Volume / Share Price
16:21 19,959 @ 3.89p
15:42 20,679 @ 3.89p
15:00 589 @ 3.89p
14:11 901 @ 3.86p
14:03 20,000 @ 3.89p

CNSL Key Personnel

CEO Jag Grewal
Chair Simon Gordon Douglas

Top of Page